Lifecore Biomedical, Inc. \de\

Name: Lifecore Biomedical, Inc. \de\ standardized financial statements, quarterly
Creator: Listed

LFCRNasdaqCIK 1005286HealthcareFiscal year ends May 25

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$34.2m, Q2 FY2027

Operating income$2.6m, Q2 FY2027

Net income−$6.2m, Q2 FY2027

Lifecore Biomedical, Inc. \de\, income statement, quarterly
Line item	Unit	Q4 FY20232023-05-28	Q1 FY20242023-08-27	Q2 FY20242023-11-26	Q3 FY20242024-02-25	Q4 FY20242024-05-26	Q1 FY20252024-08-25	Q2 FY20252024-11-24	Q3 FY20252025-02-23	Q4 FY20252025-05-25	Q1 FY20262025-09-30	Q1 FY20262026-03-31	Q2 FY20272026-06-30
Revenue	$m	31.1	24.5	30.2	35.7	37.9	24.7	32.6	35.2	36.4	31.1	23.2	34.2
Cost of revenue	$m	23.4	21.8	20.2	23.8	20.6	19.3	21.5	25.3	22.5	23.3	18.7	22.1
Gross profit	$m	7.8	2.7	10.0	11.9	17.3	5.4	11.1	9.8	14.0	7.8	4.5	12.1
Research and development	$m	2.1	2.1	2.1	2.2	2.2	2.2	1.9	2.0	2.1	2.0	1.2	1.5
Selling, general and administrative	$m	12.3	9.2	9.3	9.8	12.2	14.8	11.1	10.0	9.0	8.9	7.9	8.0
Operating income	$m	(6.6)	(8.6)	(1.5)	(0.9)	2.1	(11.6)	(2.0)	(9.0)	5.3	(3.1)	(4.7)	2.6
Interest expense	$m	3.9	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Income tax	$m	0.2	0.1	(0.1)	0.2	(0.1)	(0.0)	0.0	(0.0)	0.0	0.3	0.0	0.0
Net income	$m	(39.3)	(10.8)	14.2	15.6	(7.1)	(16.2)	(6.6)	(14.8)	(1.1)	(10.0)	(15.0)	(6.2)
Diluted EPS	$ per share	(1.32)	(0.35)	0.39	0.42	not reported	(0.53)	(0.25)	(0.42)	(0.06)	(0.29)	(0.43)	(0.19)
Basic EPS	$ per share	(1.32)	(0.35)	0.47	0.51	not reported	(0.53)	(0.25)	(0.42)	(0.06)	(0.29)	(0.43)	(0.19)

Balance sheet

Cash and equivalents$17.2m, Q2 FY2027

Long-term debt$155.1m, Q2 FY2027

Shareholders' equity−$34.1m, Q2 FY2027

Lifecore Biomedical, Inc. \de\, balance sheet, quarterly
Line item	Unit	Q2 FY20242023-11-26	Q3 FY20242024-02-25	FY20242024-05-26	Q1 FY20252024-08-25	Q2 FY20252024-11-24	Q3 FY20252025-02-23	FY20252025-05-25	period not labelled2025-06-30	Q1 FY20262025-09-30	FY20262025-12-31	Q1 FY20262026-03-31	Q2 FY20272026-06-30
Cash and equivalents	$m	3.2	3.1	8.5	5.5	9.5	5.4	8.3	not reported	18.9	17.5	20.8	17.2
Current assets	$m	76.7	76.2	81.0	74.2	81.9	84.2	85.7	not reported	83.9	82.3	77.6	83.7
Total assets	$m	246	246	254	247	255	238	239	not reported	235	232	225	230
Current liabilities	$m	40.3	36.8	38.9	40.5	35.3	31.1	30.2	not reported	30.0	23.6	20.5	21.6
Total liabilities	$m	203	187	200	207	196	190	192	not reported	198	198	205	213
Long-term debt	$m	92.1	96.3	101	106	111	125	130	not reported	136	142	149	155
Current portion of debt	$m	0.8	0.8	0.9	0.8	0.8	0.9	3.4	not reported	0.9	1.0	1.0	1.0
Shareholders' equity	$m	1.4	17.7	11.3	(3.9)	15.4	2.2	1.3	(0.9)	(10.5)	(14.2)	(28.4)	(34.1)

Cash flow

Operating cash flow−$2.2m, Q2 FY2027

Capital expenditure$513.0k, Q2 FY2027

Lifecore Biomedical, Inc. \de\, cash flow, quarterly
Line item	Unit	Q4 FY20232023-05-28	Q1 FY20242023-08-27	Q2 FY20242023-11-26	Q3 FY20242024-02-25	Q4 FY20242024-05-26	Q1 FY20252024-08-25	Q2 FY20252024-11-24	Q3 FY20252025-02-23	Q4 FY20252025-05-25	Q1 FY20262025-09-30	Q1 FY20262026-03-31	Q2 FY20272026-06-30
Operating cash flow	$k	(2,262)	(8,329)	1,288	(1,418)	8,716	(613)	(6,140)	1,199	5,347	1,762	4,700	(2,189)
Capital expenditure	$k	not reported	5,054	4,261	6,367	2,713	3,422	2,440	5,456	2,097	1,737	1,118	513
Share repurchases	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported

Diluted shares (weighted)37.57m, Q2 FY2027

Lifecore Biomedical, Inc. \de\, shares, quarterly
Line item	Unit	Q2 FY20232022-11-27	Q3 FY20232023-02-26	Q1 FY20242023-08-27	Q2 FY20242023-11-26	Q3 FY20242024-02-25	Q1 FY20252024-08-25	Q2 FY20252024-11-24	Q3 FY20252025-02-23	Q4 FY20252025-05-25	Q1 FY20262025-09-30	Q1 FY20262026-03-31	Q2 FY20272026-06-30
Diluted shares (weighted)	m shares	29.6	30.3	30.4	36.4	36.6	30.9	34.4	37.0	37.0	37.4	37.5	37.6

Shares outstanding: 37.85m at Jul 29, 2026, from the cover of the 10-Q filed Aug 5, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:30 ET. Listed shows no prices and gives no investment advice.